He has brought in some of his longstanding top teammates for the HealthLynked project, which should inspire confidence for shareholders. In that vein, the company’s recent performance should inspire accelerating excitement: For the three months ended June 30, 2019, the company reported tremendous year-over-year gains, including a 113% increase in revenue in Q2’19 compared to Q2’18, a 13% jump in patient appointments (from 4,010 in Q2’18 to 4,533 in Q2’19), and a 426% jump in “Time of Service” collections (from $152,174 in Q2’18 to $801,067 in Q2’19). The company’s sequential quarterly growth was also powerful, with a 160% increase in revenue to $1,208,390 in Q2’19 compared to $464,990 in Q1’19, a 22% jump in patient appts (from 3,712 in Q1’19 to 4,533 in Q2’19), and a 526% jump in “Time of Service” (from $127,809 in Q1’19 to $801,067 in Q2’19). https://bullishguru.com/healthlynked-hlyk-loo...ing-times/
$HLYK company is guided by a proven executer: Dr. Michael
He has brought in some of his longstanding top teammates for the HealthLynked project, which should inspire confidence for shareholders. In that vein, the company’s recent performance should inspire accelerating excitement: For the three months ended June 30, 2019, the company reported tremendous year-over-year gains, including a 113% increase in revenue in Q2’19 compared to Q2’18, a 13% jump in patient appointments (from 4,010 in Q2’18 to 4,533 in Q2’19), and a 426% jump in “Time of Service” collections (from $152,174 in Q2’18 to $801,067 in Q2’19). The company’s sequential quarterly growth was also powerful, with a 160% increase in revenue to $1,208,390 in Q2’19 compared to $464,990 in Q1’19, a 22% jump in patient appts (from 3,712 in Q1’19 to 4,533 in Q2’19), and a 526% jump in “Time of Service” (from $127,809 in Q1’19 to $801,067 in Q2’19). https://bullishguru.com/healthlynked-hlyk-loo...ing-times/
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
USDA Under Scrutiny as ASPCA Reports on Puppy Mill Violations
ASPCA's Shocking Report on Puppy Mill Violations In a recent analysis by the ASPCA, alarming statistics have surfaced regarding animal welfare violations at USDA-licensed commercial dog breeding facilities. The findings reveal that in a given year, substantial breaches of care standards were documented, yet no actions were taken to ensure the safety of the animals....
Continue Reading
PowerReviews Unveils Partner Program to Amplify UGC Value
PowerReviews Launches Comprehensive Partner Program PowerReviews, a reputable name backed by 1WorldSync, has initiated an exciting Partner Program aimed at revolutionizing the way user-generated content (UGC) is leveraged. This initiative is designed to not only boost productivity but also facilitate enhanced revenue opportunities for partners who promote its advanced...
Continue Reading
Turnspire Capital Partners Expands Portfolio with GHP Group
Turnspire Capital Partners pulled the trigger on acquiring GHP Group back in 2024, a move that sent shockwaves through the consumer product landscape. This was no random buy; GHP's got its fingers in the pie of outdoor living products—think patio heaters and grills—all under reputable brands like Dyna-Glo and Pleasant Hearth. GHP Group: A Heavyweight Player in Outdoor...
Continue Reading
MPI Corporation Launches Groundbreaking 250 GHz Probe System
Enhancing Precision in Semiconductor Testing In the fast-evolving world of semiconductor technology, precision and performance are critical. MPI Corporation has once again demonstrated its innovative spirit by unveiling a revolutionary 250 GHz broadband test solution. This state-of-the-art system combines the power of the TITAN™ Probes and MPI's extensive expertise in...
Continue Reading
Passage Bio's Gene Therapy Strategy: Hope for Dementia Treatments
Promising Advances in Gene Therapy Recently, Passage Bio, Inc. (NASDAQ: PASG), a pioneering company in genetic medicine, showcased groundbreaking preclinical and interim clinical results for its gene therapy product, PBFT02. This was presented at a major congress focused on gene and cell therapy. Designed specifically to target frontotemporal dementia associated with GRN...
Continue Reading